European Journal of Cancer
Volume 45, Issue 1 , Pages 174-182 , January 2009

A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

  • Sui Chu Chung

      Affiliations

    • Department of Pharmacology and Clinical Neuroscience, Pharmacology, Umeå University, SE-901 87 Umeå, Sweden
    • ,
  • Peter Hammarsten

      Affiliations

    • Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
    • ,
  • Andreas Josefsson

      Affiliations

    • Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
    • ,
  • Pär Stattin

      Affiliations

    • Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
    • ,
  • Torvald Granfors

      Affiliations

    • Department of Urology, Central Hospital, Västerås, Sweden
    • ,
  • Lars Egevad

      Affiliations

    • International Agency for Research on Cancer, Lyon, France
    • ,
  • Giacomo Mancini

      Affiliations

    • Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany
    • ,
  • Beat Lutz

      Affiliations

    • Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany
    • ,
  • Anders Bergh

      Affiliations

    • Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
    • ,
  • Christopher J. Fowler

      Affiliations

    • Department of Pharmacology and Clinical Neuroscience, Pharmacology, Umeå University, SE-901 87 Umeå, Sweden
    • Corresponding Author InformationCorresponding author: Tel.: +46 90 7851510; fax: +46 90 7852752.

Received 20 August 2008 ,Revised 3 October 2008 ,Accepted 15 October 2008.

References 

  1. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
  2. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc. 2005;80(7):899–907
  3. Graham J, Baker M, Macbeth F, Titshall V Guideline Development Group. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ. 2008;336(7644):610–612
  4. Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? a conceptual review. Cancer. 2007;110(12):2604–2613
  5. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why?. Nat Clin Pract Oncol. 2007;4(12):692–698
  6. Howlett AC, Barth F, Bonner T, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202
  7. Fowler CJ. The cannabinoid system and its pharmacological manipulation – a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol. 2006;20(6):549–562
  8. Gómez-Ruiz M, Hernández M, de Miguel R, Ramos JA. An overview on the biochemistry of the cannabinoid system. Mol Neurobiol. 2007;36(1):3–14
  9. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745–755
  10. Bifulco M, Laezza C, Pisanti S, Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Brit J Pharmacol. 2006;148(2):123–135
  11. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008;68(2):339–342
  12. Flygare J, Sander B. The endocannabinoid system in cancer – potential therapeutic target?. Semin Cancer Biol. 2008;18(3):176–189
  13. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005;65(5):1635–1641
  14. Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000;141(1):118–126
  15. Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart JP. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56(1):1–12
  16. Sánchez MG, Sánchez AM, Ruiz-Llorente L, Díaz-Laviada I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett. 2003;555(3):561–566
  17. Nithipatikom K, Endsley MP, Isbell MA, et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64(24):8826–8830
  18. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 2006;281(51):39480–39491
  19. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6):538–542
  20. Datta MW, True LD, Nelson PS, Amin MB. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol. 2007;14(6):408–418
  21. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Human Mol Genet. 2001;10(7):657–662
  22. Josefsson A, Wikström P, Granfors T, et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol. 2005;48(4):577–583
  23. Grimsey NL, Goodfellow CE, Scotter EL, Dowie MJ, Glass M, Graham ES. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal. J Neurosci Meth. 2008;171(1):78–86
  24. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214(1):173–180
  25. Börner C, Höllt V, Kraus J. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation. 2008;14(6):281–286
  26. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54–61
  27. Ruiz-Llorente L, Sánchez MG, Carmena MJ, et al. Expression of functionally active cannabinoid receptor CB1 in the human prostate gland. Prostate. 2003;54(2):95–102
  28. Tokanovic S, Malone DT, Ventura S. Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Brit J Pharmacol. 2007;150(2):227–234
  29. Endsley MP, Aggarwal N, Isbell MA, et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer. 2007;121(5):984–991
  30. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007;1773(8):1213–1226
  31. Zheng D, Bode AM, Zhao Q, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 2008;68(10):3992–3998
  32. Endsley MP, Thill R, Choudhry I, et al. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 2008;123(6):1318–1326
  33. Michalski CW, Oti FE, Erkan M, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008;122(4):742–750
  34. Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31–38
  35. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534

PII: S0959-8049(08)00810-1

doi: 10.1016/j.ejca.2008.10.010

European Journal of Cancer
Volume 45, Issue 1 , Pages 174-182 , January 2009

Article Tools

* Image Usage & Resolution